“No doubt about it and you're seeing IMMU get gr
Post# of 154338
(Total Views: 542)
Posted On: 04/06/2020 11:32:53 AM
“No doubt about it and you're seeing IMMU get great press.”
You’re obviously not good at conducting independent DD because if you were you’d realize that IMMU’s sacituzumab govitectan is YEARS ahead of testing in relation to mTNBC when compared to Leronlimab. In fact, IMMU has already submitted a BLA as a 3rd line treatment for mTNBC. Second, IMMU’s drug has been through a couple of trials and has been tested in many more patients. They are getting great press because they have an established drug, with data, are on the NASDAQ, and have partnerships with some major BPs.
“and we (CYDY) were supposed to be out front in the solid cancers market.“
CYDY is not suppose to be “out in front of the solid cancers market.” CYDY is an infant in the oncology market. CYDY would like to be out in front, but the company has only recently started cancer trials and those trials are still enrolling aka CYDY is a very young oncology biotech.
“In my opinion, just terrible planning and execution on the paperwork side.”
Not sure what “terrible planning and execution” you’re referring to here because NP got a basket trial approved by the FDA and that basket trial is enrolling as we speak. He’s also working on BTD for cancer as well and has a meeting with the FDA pending. Not sure what else you want considering the first mTNBC patient was injected near the end of 2019.
“NP bit off more than he could chew and it cost the stockholders dearly.”
I really hate to repeat myself, but CYDY is in the infancy stages as an oncology biotech. The increase in SP from .30 to the $1 range was due to cancer results so I’m not sure how you can interpret that as, “costing the stockholders dearly.” You can not compare IMMU to CYDY as IMMU is years ahead and has data from a number of trials and many, many more patients.
Also, CYDY still has the HIV and pending COVID19 indications.
Please, do your homework before posting inaccurate information.
You’re obviously not good at conducting independent DD because if you were you’d realize that IMMU’s sacituzumab govitectan is YEARS ahead of testing in relation to mTNBC when compared to Leronlimab. In fact, IMMU has already submitted a BLA as a 3rd line treatment for mTNBC. Second, IMMU’s drug has been through a couple of trials and has been tested in many more patients. They are getting great press because they have an established drug, with data, are on the NASDAQ, and have partnerships with some major BPs.
“and we (CYDY) were supposed to be out front in the solid cancers market.“
CYDY is not suppose to be “out in front of the solid cancers market.” CYDY is an infant in the oncology market. CYDY would like to be out in front, but the company has only recently started cancer trials and those trials are still enrolling aka CYDY is a very young oncology biotech.
“In my opinion, just terrible planning and execution on the paperwork side.”
Not sure what “terrible planning and execution” you’re referring to here because NP got a basket trial approved by the FDA and that basket trial is enrolling as we speak. He’s also working on BTD for cancer as well and has a meeting with the FDA pending. Not sure what else you want considering the first mTNBC patient was injected near the end of 2019.
“NP bit off more than he could chew and it cost the stockholders dearly.”
I really hate to repeat myself, but CYDY is in the infancy stages as an oncology biotech. The increase in SP from .30 to the $1 range was due to cancer results so I’m not sure how you can interpret that as, “costing the stockholders dearly.” You can not compare IMMU to CYDY as IMMU is years ahead and has data from a number of trials and many, many more patients.
Also, CYDY still has the HIV and pending COVID19 indications.
Please, do your homework before posting inaccurate information.
(12)
(0)